Jammu Journal

Neuropathic Pain Market to witness growth by 2032, estimates DelveInsight | NEVRO CORP., Lilly, Astellas Pharma Inc., Biogen, Cirtec, Integer Holdings Corporation, B. Braun SE, Medtronic, Abbott, etc

 Breaking News
  • No posts were found

Neuropathic Pain Market to witness growth by 2032, estimates DelveInsight | NEVRO CORP., Lilly, Astellas Pharma Inc., Biogen, Cirtec, Integer Holdings Corporation, B. Braun SE, Medtronic, Abbott, etc

April 02
07:35 2024
Neuropathic Pain Market to witness growth by 2032, estimates DelveInsight | NEVRO CORP., Lilly, Astellas Pharma Inc., Biogen, Cirtec, Integer Holdings Corporation, B. Braun SE, Medtronic, Abbott, etc
Neuropathic Pain Market

(Albany, USA) DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Neuropathic Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Neuropathic Pain market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Neuropathic Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Neuropathic Pain market.

 

Request for a Free Sample Report @ Neuropathic Pain Market Forecast

 

Some facts of the Neuropathic Pain Market Report are:

  • According to DelveInsight, Neuropathic Pain market size is expected to grow at a decent CAGR by 2032.
  • Leading Neuropathic Pain companies working in the market are NEVRO CORP., Lilly, Astellas Pharma Inc., Biogen, Cirtec, Integer Holdings Corporation, B. Braun SE, Medtronic, Abbott, Boston Scientific Corporation, OMRON Healthcare Co., Ltd., electroCore, Inc., Polar Medical Ltd, SunMED Medical, NeuroMetrix, WEX Pharmaceuticals Inc, Lexicon Pharmaceuticals, Bayer, and others.
  • Key Neuropathic Pain Therapies expected to launch in the market are Halneuron, LX9211, BAY2395840, and others.
  • This growth can be attributed to the escalating prevalence of disease burdens across the 7MM, along with heightened awareness initiatives concerning neuropathic pain by both governmental bodies and patient associations. The market’s expansion is further propelled by a robust pipeline of innovative therapeutic possibilities encompassing both pharmaceutical and non-pharmaceutical interventions. Nonetheless, the increasing awareness, the development of diagnostic tools for neuropathy, and the demand for fresh treatment avenues collectively represent promising opportunities within the neuropathic pain market.
  • On Feb 2024, EMS announced a National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain.
  • On Feb 2024, Lexicon Pharmaceuticals announced a Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS).
  • On Aug 2023, NeuraLace Medical, announced a Multicenter, Randomized, Clinical Trial Comparing the Safety and Effectiveness of Axon Therapy and Conventional Medical Management (AT+CMM) for the Treatment of Painful Diabetic Neuropathy to Sham and Conventional Medical Management (Sham+CMM).

 

Neuropathic Pain Overview

Neuropathic pain is a chronic condition resulting from damage or dysfunction of the nervous system, characterized by shooting or burning sensations, tingling, numbness, and hypersensitivity. It can arise from various causes, including nerve injury, diabetes, infection, autoimmune disorders, and conditions like multiple sclerosis or stroke.

Unlike nociceptive pain, which occurs in response to tissue damage, neuropathic pain arises from aberrant signaling within the nervous system. This can involve peripheral nerves, spinal cord, or brain pathways. Diagnosis often involves a thorough medical history, physical examination, and sometimes imaging or nerve conduction studies to identify the underlying cause.

Management of neuropathic pain is challenging and typically involves a multidisciplinary approach. Treatment options may include medications such as anticonvulsants, antidepressants, and opioids, as well as topical agents, nerve blocks, physical therapy, and psychological interventions. However, effective management often requires individualized treatment plans tailored to the specific cause and characteristics of the neuropathic pain.

 

Learn more about Neuropathic Pain treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/neuropathic-pain-market

 

Neuropathic Pain Market 

The Neuropathic Pain market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Neuropathic Pain market trends by analyzing the impact of current Neuropathic Pain therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Neuropathic Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neuropathic Pain market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Neuropathic Pain market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Neuropathic Pain Epidemiology

The Neuropathic Pain epidemiology section provides insights into the historical and current Neuropathic Pain patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Neuropathic Pain market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Neuropathic Pain Epidemiology @ Neuropathic Pain Market Dynamics

 

Neuropathic Pain Drugs Uptake

This section focuses on the uptake rate of the potential Neuropathic Pain drugs recently launched in the Neuropathic Pain market or expected to be launched in 2019-2032. The analysis covers the Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Neuropathic Pain Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Neuropathic Pain market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Neuropathic Pain Pipeline Development Activities

The Neuropathic Pain report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Neuropathic Pain key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Neuropathic Pain pipeline development activities @ https://www.delveinsight.com/sample-request/neuropathic-pain-market

 

Neuropathic Pain Therapeutics Assessment

Major key companies are working proactively in the Neuropathic Pain Therapeutics market to develop novel therapies which will drive the Neuropathic Pain treatment markets in the upcoming years are WEX Pharmaceuticals Inc, Lexicon Pharmaceuticals, Bayer, and others.

 

Learn more about the emerging Neuropathic Pain therapies & key companies @ https://www.delveinsight.com/sample-request/neuropathic-pain-market

 

Neuropathic Pain Report Key Insights

1. Neuropathic Pain Patient Population

2. Neuropathic Pain Market Size and Trends

3. Key Cross Competition in the Neuropathic Pain Market

4. Neuropathic Pain Market Dynamics (Key Drivers and Barriers)

5. Neuropathic Pain Market Opportunities

6. Neuropathic Pain Therapeutic Approaches

7. Neuropathic Pain Pipeline Analysis

8. Neuropathic Pain Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Neuropathic Pain Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Neuropathic Pain Competitive Intelligence Analysis

4. Neuropathic Pain Market Overview at a Glance

5. Neuropathic Pain Disease Background and Overview

6. Neuropathic Pain Patient Journey

7. Neuropathic Pain Epidemiology and Patient Population

8. Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Neuropathic Pain Unmet Needs

10. Key Endpoints of Neuropathic Pain Treatment

11. Neuropathic Pain Marketed Products

12. Neuropathic Pain Emerging Therapies

13. Neuropathic Pain Seven Major Market Analysis

14. Attribute Analysis

15. Neuropathic Pain Market Outlook (7 major markets)

16. Neuropathic Pain Access and Reimbursement Overview

17. KOL Views on the Neuropathic Pain Market

18. Neuropathic Pain Market Drivers

19. Neuropathic Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting